Core Viewpoint - Fosun United Health Insurance Co., Ltd. has successfully completed a strategic capital increase of 810 million yuan, raising its registered capital from 694.44 million yuan to 1.01085 billion yuan, marking a significant milestone in its capital strength and shareholder structure [1][2]. Group 1: Capital Increase Details - On September 22, 2023, Fosun United Health received approval from the Guangdong Financial Regulatory Bureau for a capital increase of 810 million yuan [1]. - The capital increase involved new shareholders, including the International Finance Corporation (IFC) and the Asian Development Bank (ADB), while existing shareholder Fosun Pharma increased its stake from 14% to 20.05% [1]. - The capital increase is expected to provide a solid foundation for the company's future high-quality development and business expansion [1]. Group 2: Financial Performance - Since its establishment in January 2017, Fosun United Health has seen a continuous expansion in premium income, with insurance business revenue growing from 5.9 million yuan in 2017 to 5.226 billion yuan in 2024 [2]. - In the first half of 2025, the company achieved insurance business revenue of 3.642 billion yuan, representing a year-on-year growth of 31.09%, and net profit of 33 million yuan, marking a return to profitability [2]. - Despite previous attempts at capital increases in 2018, 2019, 2021, and 2023 failing, the company received cash donations from shareholders to supplement its capital during that period [2]. Group 3: Solvency Position - As of the end of 2022, the core solvency adequacy ratio of Fosun United Health dropped to 56.77%, and the comprehensive solvency adequacy ratio fell to 113.55%, nearing regulatory limits [3]. - By the end of 2023, these solvency ratios further declined to 55.34% and 110.67%, respectively [3]. - Following the capital increase in April 2024, the company's solvency ratios improved significantly, with the core solvency adequacy ratio reaching 114.88% and the comprehensive solvency adequacy ratio at 166.85% by June 2025 [3].

时隔一年半，复星联合健康保险股份有限公司（下称"复星联合健康"）再迎增资。 复星联合健康表示，这是公司自成立以来的一项重要里程碑，标志着公司在资本实力、股东结构和偿付 能力等方面实现全面升级。通过此次战略注资，公司不仅进一步夯实了资本基础，也为后续高质量发展 和业务拓展提供了坚实支撑。 作为专业健康险公司"七子"之一，复星联合健康成立于2017年1月，注册地位于广东省广州市，专业提 供健康保障及健康管理服务。 成立8年多来，复星联合健康保费规模持续扩张。2017年至2024年，公司分别实现保险业务收入0.59亿 元、5.2亿元、18.19亿元、24.54亿元、37.14亿元、38.79亿元、41.25亿元、52.26亿元，同期净利润分别 为-0.45亿元、-0.87亿元、-0.71亿元、-0.74亿元、0.33亿元、0.64亿元、0.23亿元、0.42亿元。 2025年上半年，复星联合健康实现保险业务收入36.42亿元，同比增长31.09%；净利润0.33亿元，同比 扭亏为盈。 9月22日，复星联合健康发布公告，宣布战略增资落地。公司于当日正式获得广东金融监管局批复，核 准增资8.1亿元，注册资本由6.944 ...